Litigation Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Docket		Date Filed	2017-06-30
Court	District Court, N.D. West Virginia	Date Terminated	2020-06-22
Cause	35:271 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To	James P. Mazzone
Parties	MYLAN PHARMACEUTICALS INC.
Patents	10,029,015; 6,509,376; 6,926,907; 7,320,999; 7,619,001; 7,803,840; 8,013,002; 8,399,514; 8,759,393; 9,018,017; 9,024,096
Attorneys	Travis L. Zeik
Firms	Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Link to Docket	External link to docket

Biologic Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.

Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-06-30	1	Complaint	“the ‘999 patent”), 7,619,001 (“the ‘001 patent”), 7,803,840 (“the ‘840 patent”), 8,759,393 (“the ‘393…- 376 Patent, # 2 Exhibit B - 999 Patent, # 3 Exhibit C - 001 Patent, # 4 Exhibit D - 840 Patent, # 5 …is an action for patent infringement of U.S. Patent Nos. 6,509,376 (“the ‘376 patent”), 7,320,999 (“the…393 patent”) and 8,399,514 (“the ‘514 patent”) arising under the patent laws of the United States, Title…5 Exhibit E - 393 Patent, # 6 Exhibit F - 514 Patent, # 7 Civil Cover Sheet)(lmm) (Entered: 06/30/2017	External link to document
2018-10-12	142	Status Report	infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), 7,619,001 … (“the ’001 patent”), 7,803,840 (“the ’840 patent”), 8,759,393 (“the ’393 patent”) and 8,399,514 … the patents-in-suit. The ’393 patent has expired. It is Mylan’s position that this patent should be…partes review (“IPR”) of Biogen’s ’514 patent. Biogen’s Patent Owner’s Preliminary Response is due on…for regulatory patent term extension (“PTE”) on the ’376, ’999, ’001, and ’840 patents. Under the relevant	External link to document
2019-02-04	196	Stipulation and Order	affirmative defenses related to U.S. Patent Nos. 6,509,376; 7,320,999; 7,803,840; and 8,759,393. The parties…counterclaims and affirmative defenses as to U.S. Patent Nos. 7,619,001 and 8,399,514. Signed by Senior …2017 22 June 2020 1:17-cv-00116 835 Patent - Abbreviated New Drug Applications (ANDA)	External link to document
2019-10-08	288	Order	Parties to this patent infringement case involving U.S. Patent Nos. 8,399,514 (“the °514 patent”) and 7,619,001… 15-16 of the °514 patent and claims 1-3, 6-9, 12-19, and 22-24 of the *001 patent under 35 U.S.C. § 271…and 15-16 of the 514 patent and claims 1-3, 6-9, 12-19, and 22-24 of the °001 patent are not invalid and…7,619,001 (‘the 001 patent”); WHEREAS the Parties wish to narrow the issues in this litigation; WHEREAS…that it will not assert claims 17-19 of the 514 patent against Mylan (see ECF 102); THEREFORE, IT IS	External link to document
2020-01-02	299	Notice (Other)	Rajendra Kumar Joshi; Hans- 6,509,376 1/21/03 United…invalidate U.S. Patent Nos. 7,619,001 (“the ’001 patent”) and 8,399, 514 (“the ’514 patent”) (collectively… the “patents-in-suit”) and/or show the state of the art relative to the asserted patents. … Patents and File Histories Date of Issue/ Patent/Patent… Date of Issue/ Patent/Patent Publication Country of Publication	External link to document